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Abstract
Background: 4-Hydroxycoumarin (4-HC) is a coumarin that lacks anticoagulant activity. 4-HC
affects the cytoskeletal stability and decreases cell adhesion and motility of the melanoma cell line
B16-F10. Together with integrins and other cytoskeletal proteins, paxillin participates in the
regulation of cell adhesion and motility, acting as an adapter protein at focal adhesions. The present
study determined the participation of paxillin in the reported effects of 4-HC and analyzed the role
of paxillin in the formation of melanoma metastases.
Results: 4-HC decreased protein and mRNA levels of α- and β-paxillin isoforms in B16-F10 cells.
Paxillin downregulation correlated with an inadequate translocation of paxillin to focal adhesions
and a reduced phosphotyr118-paxillin pool. Consequently, 4-HC altered paxillin-mediated signaling,
decreasing the phosphorylation of FAK and the level of GTP-bound Rac-1. These results partially
explain the mechanism of the previously reported effects of 4-HC. Additionally, we studied the
effect of 4-HC on metastatic potential of B16-F10 cells through experimental metastasis assays. In
vitro treatment of cells with 4-HC inhibited their capability to originate pulmonary metastases. 4-
HC did not affect cell proliferation or survival, demonstrating that its antimetastatic effect is
unrelated to changes on cell viability. We also studied the importance of paxillin in metastasis by
transfecting melanoma cells with paxillin-siRNA. Transfection produced a modest reduction on
metastatic potential, indicating that: i) paxillin plays a role as inducer of melanoma metastasis; and
ii) paxillin downregulation is not sufficient to explain the antimetastatic effect of 4-HC. Therefore,
we evaluated other changes in gene expression by differential display RT-PCR analysis. Treatment
with 4-HC produced a downregulation of Adhesion Regulating Molecule-1 (ARM-1), which
correlated with a decreased adhesion of melanoma cells to lung slides.
Conclusion: This study shows that reduced paxillin expression is associated with the impaired cell
adhesion and motility seen in 4-HC-treated cells and partially contributes to the antimetastatic
effect of 4-HC. In contrast, the role of ARM-1 reduced expression in the effects of 4-HC is still to
be clarified. The antimetastatic effect of 4-HC suggests that this compound, or others with similar
mode of action, might be useful for the development of adjuvant therapies for melanoma.
Published: 20 May 2008
Cancer Cell International 2008, 8:8 doi:10.1186/1475-2867-8-8
Received: 25 March 2008
Accepted: 20 May 2008
This article is available from: http://www.cancerci.com/content/8/1/8
© 2008 Velasco-Velázquez et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cancer Cell International 2008, 8:8 http://www.cancerci.com/content/8/1/8
Page 2 of 12
(page number not for citation purposes)
Background
Formation of metastases is still the leading cause of death
in advanced melanoma patients, regardless the numerous
innovations on the treatment of the disease. Hence, the
search of therapeutic agents that can inhibit metastasis is
crucial for improving the management of melanoma.
The production of metastases is a highly complex process
by which some cancer cells move away from the primary
tumor and colonize other organs. This process requires
phenotypical changes that allow cancer cells to migrate,
survive in the blood circulation, extravasate, and prolifer-
ate in a tissue with a different microenvironment [1].
Along the metastatic cascade, cell adhesion is an essential
process [2]. Cell adhesion mediated by integrin receptors
drives the formation of focal adhesions, which are multi-
molecular structures that enable cells to firmly adhere.
Additionally, focal adhesions constitute important signal-
ing centers that regulate the reorganization of the
cytoskeleton needed for spreading and motility [3,4].
These functions are critical in the acquisition of the ability
of cancer cells to invade distant tissues [2]; consequently,
the focal adhesion molecules have been proposed as phar-
macological targets for decreasing invasiveness of cancer
cells [5,6].
Paxillin is a multidomain adapter protein that participates
in linking scaffolding and in signaling at focal adhesions
[7]. The structural features of paxillin (reviewed by Brown
and Turner [7]) allow it to interact with different signaling
proteins, such as FAK, Src, Crk, Csk, p120 RasGAP, and
PTP-PEST [7,8]. Thus, paxillin has been implicated in the
regulation of diverse cellular events, including adhesion
[9,10], spreading [11], and motility [11,12].
In mouse, two isoforms of paxillin are generated by alter-
native splicing, with molecular weights of 68 (α) and 70
KDa (β) [13,14]. Even when both isoforms may share the
same functions [14], the β isoform has been implicated in
transformation and malignancy [13]. Both paxillin iso-
forms contain critical phosphorylation sites at tyrosines
31 and 118 [7,12]. The phosphorylation of these two tyro-
sines by FAK and Src regulates the paxillin turnover in
focal adhesions [15-17] and generate docking sites for
other molecules that participate in the rearrangement of
the actin cytoskeleton [7,16-19]. Then, tyrosine phospho-
rylation of paxillin and its localization into focal adhe-
sions are necessary for the adequate control of adhesion
and motility [12,17-19].
In cancer cells, overexpression and increased tyrosine
phosphorylation of paxillin have been reported. For
example, paxillin overexpression stimulates the adhesion
of squamous carcinoma cells to collagen [20] as well as
their migration [21]. Paxillin is also overexpressed in
highly metastatic human osteosarcoma [22] and renal car-
cinoma cell lines [23]. Similarly, levels of phospho-paxil-
lin are much higher in melanoma cell lines than in
melanocytes [24]. These data suggest that paxillin plays a
role in the acquisition and maintenance of a malignant
phenotype.
4-Hydroxycoumarin (4-HC) is a simple coumarin used as
precursor for the synthesis of anticoagulant drugs and
rodenticides that are 3-substituted-4-hydroxicoumarins;
however, 4-HC lacks of anticoagulant activity [25]. Previ-
ously, we have provided evidence that 4-HC affects the
stability of the actin cytoskeleton on the melanoma cell
line B16-F10, impairing the formation of stress fibers and
lamellipodia [26]. These effects correlate with reductions
in cell adhesion to extracellular matrix proteins and inhi-
bition of motility [26]. The key role of paxillin in the reg-
ulation of cytoskeletal rearrangements, adhesion, and
motility led us to the proposal that paxillin may be
involved in the reported effects produced by 4-HC. There-
fore, we analyzed the effects of 4-HC on paxillin expres-
sion and paxillin-mediated signaling. Additionally, we
evaluated the metastatic potential of B16-F10 cells treated
with 4-HC, and studied the role of paxillin in metastasis
by blocking its expression with siRNA. Finally, we per-
formed differential display RT-PCR assays in order to
identify other proteins that participate in the effects of 4-
HC.
Methods
Materials
The murine melanoma cell line B16-F10 was purchased
from the American Type Culture Collection (Manassas,
VA, USA). C57BL/6 mice (Harlan, Mexico City, Mexico)
were used in this study. The experiments with mice were
conducted in accordance with the Guide for the Care and
Use of Laboratory Animals as adopted and promulgated
by the Declaration of Helsinki.
4-Hydroxycoumarin (4-Hydroxy-2H-1-benzopyran-2-
one [cat. no. H23805]) and its vehicle, ethanol, were pur-
chased from Sigma (St. Louis, MO, USA). Antibodies
against paxillin (sc-5574 rabbit polyclonal), β-tubulin (D-
10 mouse monoclonal), FAK (H-1 mouse monoclonal),
and phosphotyrosine (PY20 mouse monoclonal) as well
as siRNAs were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Control siRNA (sc-37007) is a
non-targeting 20–25 nt siRNA that will not lead to the
specific degradation of any known cellular mRNA, while
paxillin siRNA (sc-36197) is a pool of 3 target-specific 20–
25 nt siRNAs.
Cell culture and treatments
B16-F10 cells were routinely cultured at 37°C in a humid
5% CO2 atmosphere, using RPMI-1640 containing 10%Cancer Cell International 2008, 8:8 http://www.cancerci.com/content/8/1/8
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fetal bovine serum (FBS). For all experiments cells were
seeded at a density of 3 × 104 cells/cm2. In experiments
with 4-HC, cells were incubated overnight and then
exposed for 24 h to 500 μM 4-HC (dissolved in ethanol)
or 0.75% ethanol (control) in serum-free medium. The
concentration and exposure time used here were previ-
ously reported [26], and are those that induce changes in
actin cytoskeleton, impairing cell adhesion and motility.
Transfection with siRNA (60 pmols) was carried out with
Lipofectamine 2000 (Invitrogen, Rockville, MD, USA)
according to the procedure recommended by the manu-
facturer.
Analysis of paxillin expression and phosphorylation
Treated cells were washed twice with ice-cold PBS and
lysed in cold lysis buffer [50 mM Tris (pH 8.0), 150 mM
NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS] contain-
ing a protease inhibitor cocktail (Roche, Indianapolis, IN,
USA). Samples containing 60 μg of total protein were sep-
arated by SDS-PAGE and transblotted onto PVDF mem-
branes. The membranes were blocked and then probed
with anti-paxillin or with anti-phosphotyr118-paxillin
antibodies. On both cases the membranes were stripped
and reprobed with anti-β-tubulin antibody. After incuba-
tion with the corresponding secondary antibody, the
immunoreactive bands were visualized by chemiluminis-
cence and a densitometric analysis was carried out using
ImageJ NIH software [27].
Immunoflurescence
Cellular localization of paxillin was evaluated on cells
seeded on Labtek chambers (Nunc, Rochester, NY, USA).
After treatment, cells were fixed with 4% formaldehyde in
PBS and permeated during 4 min at room temperature
with 0.1% Triton X-100 diluted in PBS. Then, paxillin was
labeled using anti-paxillin antibody followed by a second-
ary antibody conjugated with Alexa-546 (Molecular
Probes, Eugene, OR, USA). After extensive washing, the
slides were mounted and analyzed with a Nikon epifluo-
rescence microscope (Melville, NY, USA).
Reverse transcription-polymerase chain reaction (RT-
PCR)
Total RNA was extracted using Trizol reagent (Invitrogen)
according to the manufacturer's instructions and quanti-
fied spectrophotometrically at 260 nm. Synthesis of
cDNA was carried out using Super-Script reverse tran-
scriptase (Invitrogen) and oligo-dT as primer. Semiquan-
titative PCR was performed in 50 μl of a reaction mixture
containing 1× PCR buffer, 2.5 mM MgCl2, 0.2 mM dNTPs,
1·U AmpliTaq DNA polymerase (Invitrogen), 0.2 μM of
each primer, and cDNA obtained from 175 ng of total
RNA. Reactions were cycled 30 times through 30 s at
94°C, 60 s at 55°C, and 60 s at 72°C. The paxillin primers
used were previously reported by Mazaki et. al. [14] and
are as follows: pan-paxillin: sense 5'-aacaagcagaagtcagca-
gagcc-3', antisense 5'-ctagcttgttcaggtcggac-3' (amplicon
length: 582 bp for α isoform and 684 bp for β isoform);
β-paxillin: same sense primer than for pan-paxillin, anti-
sense 5'-ctctccatccactctctgtt-3' (503 bp). The GAPDH
primers [28] were: sense 5'-accacagtccatgccatcac-3', anti-
sense 5'-tccaccaccctgttgctgta-3' (452 bp). PCR products
were resolved by 2% agarose gel electrophoresis and
stained with ethidium bromide. Negative controls lacking
reverse transcriptase were run in parallel to confirm that
samples were not contaminated with genomic DNA.
Real time PCR for ARM-1 was performed in a GeneAmp
5700 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) as described previously [29 javas-
cript:popRef('b12')]. Briefly, 0.5× of SYBR Green I (Molec-
ular Probes, Eugene, OR, USA) was added to the reaction
mixture described above. The primers for amplification of
ARM-1 were: sense 5'-ggacagcttggccctctcat-3'; antisense 5'-
gggcaaatcacaatcaccactac-3'. Reactions for GAPDH were
performed with the same primers used in semiquantita-
tive PCR. Real time-PCR reactions were cycled 35 times
through 30 s at 95°C, 30 s at 60°C, 60 s at 72°C, and 5 s
at temperature of fluorescence acquisition (FA). Data were
analyzed with the GeneAmp 5700 SDS software version
1.3 (Applied Biosystems).
Analysis of FAK phosphorylation
Lysates from adhered cells were obtained with cold lysis
buffer containing phosphatase inhibitors [1 mM sodium
pyrophosphate; 1 mM sodium orthovanadate; 50 mM
sodium fluoride]. Lysates were immunoprecipitated with
anti-FAK antibody bound to protein A- agarose beads. The
immunoprecipitated proteins were recovered adding SDS
sample buffer, separated by SDS-PAGE, transblotted onto
PVDF membranes, and probed with anti-phosphotyro-
sine and anti-paxillin antibodies. The same membranes
were reprobed with anti-FAK antibody.
Affinity precipitation of activated Rac-1
Pull-down assays for Rac-1 were performed using EZ-
Detect activation kit from Pierce (Rockford, IL, USA),
according to the manufacturer's instructions. Briefly, 106
cells were lysed in 400 μl of cold lysis buffer as described
above. The samples were mixed with GST-PAK1-PBD,
loaded on SwellGel immobilized glutathione disks, and
incubated with constant agitation at 4°C for 2 h. Then,
the disks were washed and the glutathione-bound Rac-1
(active form) was recovered adding SDS sample buffer [60
mM Tris-HCl (pH 6.8); 2% SDS; 0.05% 2-mercaptoetha-
nol; 1% glycerol; and 0.05% bromophenol blue]. The iso-
lated proteins as well as aliquots of cell lysates were
separated by electrophoresis and Rac-1 was detected by
immunoblotting using anti-Rac-1 monoclonal antibody.Cancer Cell International 2008, 8:8 http://www.cancerci.com/content/8/1/8
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Neutral red assay
Cell viability was determined using the neutral red accu-
mulation assay [30]. The cells were plated on 96-well
plates and then treated as described above. After 12, 24,
36 or 48 h of exposure to 4-HC, the medium was changed
and the cells were incubated for 90 min under cell culture
conditions with 50 μg/ml neutral red. After this incuba-
tion the cells were fixed on the plate with an aqueous solu-
tion containing 1% formaldehyde and 1% calcium
chloride and then lysed with 50% ethanol/49% water/1%
acetic acid. The concentration of accumulated neutral red
as a marker for cell viability was measured spectrophoto-
metrically at 560 nm.
Clonogenic assay
Cell survival was evaluated accordingly to the methodol-
ogy reported by Franken et. al. [31]. Briefly, cells were har-
vested and counted after treatment. Cell suspensions from
each treatment were diluted in RPMI-1640 with 5% FBS,
and immediately re-plated in 6-well plates at a density of
20 cells/cm2. The plates were incubated until cells in con-
trol wells have formed sufficiently large colonies. After
that, the colonies were fixed with 6% glutaraldehyde and
stained with 0.5% crystal violet. The plates were photo-
graphed and their digital images were analyzed with
ImageJ NIH software [27] to known the colony number.
Paxillin expression, phosphorylation and localization in 4-HC-treated cells Figure 1
Paxillin expression, phosphorylation and localization in 4-HC-treated cells. A. Representative immunoblot showing 
decreased levels of both paxillin isoforms in 4-HC-treated cells. As loading control, β-tubulin was detected in the same mem-
brane. Quantification of paxillin expression (graph) was performed by densitometric analysis from 4 independent experiments. 
On each experiment, the value of the band corresponding to α-paxillin in control lane was arbitrarily set to 1. Paxillin/tubulin 
ratios (mean ± SE) were reduced in 4-HC-treated cells (open bars in graph) when compared with control cells (closed bars). B. 
Semiquantitative RT-PCR using primers for pan-paxillin (upper panel), β-paxillin (middle panel) or GAPDH (lower panel). One 
representative experiment from 3 is shown. C. Representative photomicrographs from immunofluorescences performed with 
anti-paxillin antibody. In control cells (left), paxillin was located in focal adhesions around the cell periphery; this pattern was 
modified by the treatment with 4-HC (right). Scale bar = 20 μm. D. The level of phosphotyr118-paxillin (pY118) was also dimin-
ished by 4-HC. We were only able to detect phosphorylation in the α isofom of paxillin. One representative experiment from 
3 is shown.Cancer Cell International 2008, 8:8 http://www.cancerci.com/content/8/1/8
Page 5 of 12
(page number not for citation purposes)
Experimental metastasis assay
B16-F10 cells were treated in vitro, as mentioned under
"cell culture and treatments". After treatment, cells were
detached with a non-enzymatic cell dissociation buffer [4
mM EDTA in Ca 2+ and Mg2+-free PBS], resuspended in
Hank's balanced salt solution and immediately injected
into the tail vein of 8-week old, male C57BL/6 mice. Each
mouse received 106 cells. At 2 weeks after i.v. injection
mice were euthanized, lungs were excised and the meta-
static tumors counted in a blind manner under a dissect-
ing microscopy.
Differential display reverse transcription polymerase chain 
reaction (DD-RT-PCR)
Total RNA, free of DNA contamination was used for the
DD-RT-PCR as described by Liang and Pardee [32].
Briefly, cDNA was synthesized with 200 ng of RNA and 1
μM of primer of sequence 5'-t12ca-3' to anneal. A control
reaction lacking reverse transcriptase was included to con-
firm absence of non-specific amplification from genomic
DNA. The cDNAs corresponding to 20 ng of RNA were
PCR amplified in the presence of 0.4 μM of [α-35S] dATP
(37 GBq/pmol) using primers of sequence 5'-t12ca-3' (1
μM) and 5'-gttgcgatcc-3' (0.2 μM). PCR reactions were
cycled 35 times through 50 s at 95°C, 90 s at 40°C, and
60 s at 72°C. The heat denatured PCR products were elec-
trophoresed on a urea-PAGE gel (48% urea and 6% acry-
lamide). The gels were dried and exposed to X-ray films at
-70°C. After 10–12 h the X-ray film was developed until
the DNA bands were clearly seen on the film. The DNA
bands which were differentially displayed in the autoradi-
ograph were visually selected, marked on the gel and the
band was cut with a sterile razor. The DNA extracted from
the gel was PCR amplified using the same set of primers
used in the DD-RT-PCR analysis, cloned, and sequenced.
Adhesion of melanoma cells to lung sections
To evaluate the organ-specific adhesion of tumor cells in
vitro, the method of Vink et. al. [33] was used with modi-
fications in incubation times. Briefly, fresh lungs obtained
from healthy C57BL/6 mice were embedded in TissueTeK
O.C.T compound (Poly-Labo, Strasbourg, France) and
Effect of 4-HC on the basal activation of FAK and Rac-1 Figure 2
Effect of 4-HC on the basal activation of FAK and Rac-1. A. Analysis of samples immunoprecipitated with anti-FAK anti-
body showed that basal tyrosine phosphorylation of FAK (upper panel) was decreased by 4-HC. The same membrane was 
stripped and reprobed with anti-paxillin and anti-FAK antibodies. We found no changes on the FAK-bound paxillin levels (mid-
dle panel). One representative experiment from 3 is shown. B. The active form of Rac-1 was purified using pull-down assays 
and then probed with anti-Rac-1 antibody (upper panel). Detection of Rac-1 from total lysates (lower panel) showed that the 
difference in the amount of active Rac-1 is not associated to changes on its expression. One representative experiment from 2 
is shown.Cancer Cell International 2008, 8:8 http://www.cancerci.com/content/8/1/8
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frozen at -196°C. Fresh cryostat sections (8–10 μm thick)
mounted on glass slides were first incubated with PBS/
BSA 3% for 60 min in a humid chamber. After treatment,
melanoma cells were detached with a non-enzymatic cell
dissociation buffer, resuspended in medium, and placed
on tissue sections for 30 min at 37°C with gentle agita-
tion. The slides were washed 3 times with medium to
remove nonattached cells and then fixed in paraformalde-
hyde 3% in PBS. Slides were stained with hematoxiline-
eosine and the numbers of cells attached to the cryostat
sections were counted in 10 microscopic fields.
Results
4-HC decreased the expression of paxillin, altering its 
cellular localization and the amount of phosphotyr118-
paxillin
Analysis of paxillin expression by immunoblotting
showed that B16-F10 melanoma cells normally express α
and β isoforms of paxillin (Figure 1A, control lane). Treat-
ment of cells with 4-HC decreased the expression of both
paxillin isoforms. Densitometric analyses of the immuno-
blots revealed that in 4-HC-treated cells, the β-paxillin/
tubulin and α-paxillin/tubulin ratios decreased to 35 and
50% of the control values, respectively (Figure 1A). Addi-
tionally, we performed semiquantitative RT-PCRs in order
to evaluate whether the decrements of paxillin elicited by
4-HC were produced through changes in mRNA levels.
Using pan-paxillin primers as well as specific β-paxillin
primers we found decreased mRNA expression in cells
that were treated with 4-HC (Figure 1B). Cellular localiza-
tion of paxillin can regulate its activation; thus, we studied
the paxillin localization through immunofluorescence
assays. In control cells paxillin is distributed in a punctate
pattern, presumably forming part of focal adhesions. In
contrast, in B16-F10 cells treated with 4-HC paxillin local-
ization was predominantly perinuclear (Figure 1C). As
previously reported [26], 4-HC impaired the formation of
lamellipodia and induced shrinkage of the outer enve-
lope, forming a round cell with radial filopodia attached
to adhesion points. Paxillin can be phosphorylated on
several tyrosines [34]; among them, tyrosines 31 and 118
have shown importance in the generation of signals nec-
essary for adhesion and migration [7,12]. Thus, we stud-
ied if the reduction in paxillin expression produced by 4-
HC correlated with changes in the level of phosphotyr118-
paxillin. Even when both isoforms can be phosphor-
Effect of 4-HC on cell proliferation and survival Figure 3
Effect of 4-HC on cell proliferation and survival. A. B16-F10 cells were treated with 500 μM 4-HC (triangles) or 0.75% 
ethanol (control cells; squares) and viable cells were quantified every 12 h using the neutral red accumulation assay. Experi-
ments performed in presence of 10% FBS (solid lines) showed that cell proliferation was unaffected by 4-HC (P > 0.05, 
ANOVA). When cells were treated in serum-free medium (dashed lines), the initial cell number was unaltered neither by time 
nor by 4-HC. Values are mean ± SE obtained from 3 independent experiments. B. Clonogenic assay were performed by seed-
ing 4-HC-treated cells at a density of 20 cells/cm2. After incubation for 8 d, the generated colonies were stained and counted. 
There was no difference in the colony number produced by 4-HC-treated cells or control cells. Values in the graph are mean 
± SE obtained from 3 independent experiments. The upper picture shows examples of the results.Cancer Cell International 2008, 8:8 http://www.cancerci.com/content/8/1/8
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ylated, we were able to detect phosphotyr118 only in the α
isofom of paxillin (Figure 1D). For this isoform, the
phosphotyr118-paxillin/paxillin ratio is 85% of the control
value, indicating that the reduction in phospho-paxillin is
mainly caused by paxillin downregulation.
Paxillin-mediated signaling was impaired in 4-HC-treated 
cells
Paxillin participates in the regulation of different signal-
ing pathways. We studied the activation of FAK, a key part-
ner in paxillin-meditated signaling. Basal tyrosine
phosphorylation of FAK was found in serum starved B16-
F10, as previously reported [35] (Figure 2A, control lane).
In 4-HC-treated cells, the phospho-FAK/FAK ratio
decreased to 46% of the control value (Figure 2A). How-
ever, levels of FAK-bound paxillin did not change signifi-
cantly (Figure 2A) suggesting that even when paxillin is
downregulated, the remaining paxillin supports FAK
binding.
The activation of Rac-1, which promotes the formation of
lamellipodia, can be triggered by tyrosine-phosphorylated
paxillin; therefore, we studied the activation of Rac-1 per-
forming pull-down assays. 4-HC decreased the amount of
GTP-bound Rac-1 without changing Rac-1 expression
(Figure 2B), reducing the active Rac-1/total Rac-1 ratio to
35% of the control value.
4-HC did not alter proliferation or survival of B16-F10 cells
Reduction of paxillin expression as well as decreased FAK
activation might affect cell proliferation, survival or apop-
tosis/anoikis [36]. For that reason, we studied the viability
of cell cultures exposed to 4-HC during different times. In
presence of FBS, 4-HC did not modify cell proliferation in
comparison with control cells (Figure 3A, solid lines).
When cultures were treated in serum-free medium, we
found that 4-HC caused a slight, non significant reduction
on the number of viable cells at times longer than 24 h
(Figure 3A, dashed lines). Congruously, 4-HC did not
affect the ability of single cells to grow into a colonies (Fig-
ure 3B), suggesting that cell survival is unaffected by 4-
HC.
Treatment of B16-F10 cells with 4-HC decreased their 
ability to form experimental metastases
In order to analyze the relevance of the effects produced
by 4-HC in metastasis, we evaluated the effect of 4-HC in
an experimental metastasis model. In that model, B16-
F10 cells previously treated in vitro were injected into the
tail vein of C57BL/6 mice. When control cells were intro-
duced, they metastasize to the lungs and form 55.5 ± 10.1
(mean ± SE; n = 9) black spherical colonies. In contrast, 4-
HC-treated cells formed only 8.8 ± 2.4 (mean ± SE; n = 9)
of such colonies (Figure 4). Data were analyzed with com-
puter-assisted t test and the difference was highly signifi-
cant.
Paxillin downregulation by siRNA diminished the number 
of experimental metastases
In order to study if paxillin inhibition was enough to
block the formation of metastasis, we analyzed the meta-
static potential of B16-F10 cells transfected with paxillin-
siRNA. These cells showed reduced expression of both
paxillin isoforms to levels similar of those found in 4-HC-
treated cells (Figure 5A). Employing the model described
above, we found that melanoma cells transfected with the
control-siRNA formed 58.5 ± 7.0 (mean ± SE; n = 7) pul-
monary tumors. When cells transfected with paxillin-
siRNA were injected, the number of tumors was modest
but significantly reduced to 35.7 ± 7.1 (mean ± SE; n = 7)
(Figure 5B).
Differential display RT-PCR of cells treated with 4-HC
To evaluate other changes in gene expression in
melanoma cells treated with 4-HC, we employed the dif-
ferential display RT-PCR analysis. Several transcripts were
differentially displayed between control and 4-HC-treated
cells (data not shown). One downregulated band was
purified, reamplified, cloned, sequenced, and compared
to the nucleotide database in GenBank. The transcript was
Effect of 4-HC on the formation of experimental metastases Figure 4
Effect of 4-HC on the formation of experimental 
metastases. Melanoma cells were treated in vitro with 500 
μM 4-HC for 24 h, and then injected into the tail vein of 
C57BL/6 mice. Two weeks later, mice were sacrificed and 
the macroscopic pulmonary tumors were counted. Mice 
injected with 4-HC-treated cells (triangles) showed a 7-fold 
decrease in the number of lung tumors compared with the 
mice that received control B16-F10 cells (squares). ** P = 
0.002 (Student's t test with Welch's correction). The pictures 
on the right show examples of lungs from mice injected with 
either control or 4-HC-treated cells.Cancer Cell International 2008, 8:8 http://www.cancerci.com/content/8/1/8
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identified as Adhesion Regulating Molecule-1 (ARM-1;
GeneBank accession: NM_019822).
4-HC diminished ARM-1 expression and impaired 
adhesion to lung slides
Downregulation of ARM-1 was confirmed by real time RT-
PCR. In 4-HC-treated cells, ARM-1/GAPDH ratio was
diminished 1800-fold (Figure 6A). ARM-1 expression pro-
mote adhesion to endothelial cells [37]; therefore, we
studied the effect of 4-HC on the adhesion of melanoma
cells to lung sections. Our results showed that 4-HC pro-
duced a 7-fold reduction in the number of adhered cells
(Figures 6B and 6C), suggesting that ARM-1 downregula-
tion may participate in the antimetastatic effect of 4-HC.
Discussion
Paxillin is involved in the regulation of different cellular
functions such as modulation of cytoskeletal organiza-
tion, adhesion, and motility [7-12]. Therefore, paxillin
expression and phosphorylation are important in the
acquisition of an invasive behavior. For example, paxillin
is overexpressed and hyperphosphorylated in sublines of
the osteosarcoma cell line HuO9 that are highly meta-
static, compared with the low-metastatic sublines [22].
The present study demonstrates that 4-HC decreases the
expression of both α- and β-paxillin isoforms at a tran-
scriptional level in B16-F10 cells. Paxillin downregulation
correlates with an inadequate translocation of paxillin to
focal adhesions, a decreased pool of phosphotyr118-paxil-
lin, and alterations on paxillin-mediated signaling path-
ways.
The basal phosphorylation of FAK is reduced by 4-HC.
Fully activation of FAK needs its translocation to focal
adhesions where can be hyperphosphorylated by Src [38].
Once activated, FAK can promote cell migration through
multiple signaling connections [39]. Accordingly,
increased expression of FAK has been found in numerous
neoplasms including melanoma where correlates with
increased cell motility [40] and a more aggressive pheno-
type [41]. Paxillin binding to FAK is partially responsible
of FAK translocation to focal adhesions [42,43]. The inter-
action between paxillin and FAK also promotes the tyro-
sine phosphorylation of paxillin [44], which in turn may
alter paxillin binding affinity to FAK [42]. Thus, the for-
mation of a FAK-paxillin complex is involved in the regu-
lation of dynamics of both proteins and in the activation
of signaling pathways required for migration. We found
that 4-HC reduced the basal phosphorylation of FAK
without altering the paxillin binding to FAK. This suggests
that paxillin downregulation plays a minor role in
reduced FAK phosphorylation. Accordingly, paxillin -/-
cells show only a small but consistent decrement in phos-
phorylated FAK [45]. On the other hand, the localization
of paxillin at focal adhesions is highly dependent on the
integrity and dynamics of actin networks [46]. In
endothelial cells treated with cytochalasin D to disrupt
actin microfilaments, paxillin almost totally disappear
from focal adhesions [46]. Since the formation of stress
fibers is inhibited by 4-HC [26], we hypothesize that
reductions in activated FAK and tyrosine-phosphorylated
paxillin are caused by a restrain of paxillin-FAK complex
to reach focal adhesions.
Effect of paxillin-siRNA on the formation of experimental metastases Figure 5
Effect of paxillin-siRNA on the formation of experimental metastases. A. Immunoblot showing that paxillin expres-
sion was reduced in B16-F10 cells transfected with paxillin-siRNA (pax). Densitometric quantification (graph) show that the 
decrements on paxillin/tubulin ratios (mean ± SE, n = 3) in cells transfected with paxillin-siRNA (open bars) were similar to 
those produced by 4-HC. B. The participation of paxillin in metastasis formation was studied by injecting into mice cells trans-
fected with either paxillin- or control-siRNA. Paxillin downregulation produced a 1.6-fold reduction in the number of experi-
mental pulmonary metastases. * P = 0.04 (Student's t test). The pictures on the right show examples of lungs from mice 
injected with siRNAs-trated cells.Cancer Cell International 2008, 8:8 http://www.cancerci.com/content/8/1/8
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4-HC also decreased the basal activation of Rac-1, a down-
stream effector of paxillin, indicating that reduced paxillin
expression affects this pathway involved in the regulation
of motility. The participation of tyrosine-phosphorylated
paxillin in Rac-1 activation is well documented [47,48].
The phosphorylation of tyrosines 31 and 118 on paxillin
generate binding sites for the adaptor protein Crk [47].
Crk-paxillin interaction promotes the binding of
DOCK180 to Crk, which in turn locally activates Rac-1
[48]. Once activated, Rac-1 has a key role in cell motility
through its ability to stimulate lamellipodium protrusion
at the leading edge [4,49]. Then, the reduced Rac-1 activa-
tion in 4-HC-treated cells, which correlates with the lack
of lamellipodia previously reported [26], seems to be sub-
sequent to the reduced phospho-paxillin level. Notori-
ously, basal activation of Rac-1 is increased in B16-F10
cells relative to the poorly metastatic B16-F0 cells [50];
therefore, impaired Rac-1 activation by 4-HC may be
cooperating to decrease the metastatic behavior of B16-
F10 cells.
Changes in paxillin expression or FAK activation can pro-
mote alterations on cell proliferation and survival [36,39].
In this study we found that exposition to 4-HC during 48
h did not modify cell proliferation, indicating that in B16-
F10 cells this process is unaffected by paxillin downregu-
lation. Cell survival was also unaltered by 4-HC, demon-
strating that the antimetastatic effect of 4-HC is not related
to changes in long term survival of melanoma cells. The
lack of cytotoxic effect of 4-HC on cancer cells reported
here is consistent with previous studies [26,51]. Further-
more, 4-HC (500 μM) does not affect the viability or the
cytoskeleton stability of B82 fibroblasts [26] and is non-
toxic to cultured hepatocytes [52], supporting the hypoth-
esis that 4-HC has low toxicity.
Additionally, our results show that paxillin downregula-
tion, either by 4-HC or paxillin-siRNA, reduce the meta-
static potential of B16-F10 cells. Contrary to other
molecules involved in the regulation of adhesion, such as
integrins or FAK, the role of paxillin in the biology of
metastasis is still controversial. Several reports identify
paxillin as an inducer of metastasis; for instance, in head
and neck cancers that have metastasized to lymph nodes
paxillin expression is increased [53]. Similarly, paxillin
up-regulation correlates with the presence of extrahepatic
metastasis in hepatocellular carcinoma [54] and lymph
node metastasis in breast tumors [55]. On the contrary,
other reports state that paxillin overexpression is a marker
of a less invasive tumor phenotype in breast [56] and lung
[57] carcinomas. The fact that metastatic potential of B16-
F10 cells is reduced by decreasing paxillin expression sup-
port the hypothesis that paxillin facilitates metastasis and
emphasize the importance of paxillin as an inducer of
melanoma metastasis. Nevertheless, the number of pul-
monary metastases produced by paxillin-silenced cells is
4-fold greater than the quantity produced by 4-HC-treated
cells, indicating that paxillin downregulation is only par-
tially responsible for the antimetastatic effect of 4-HC.
To further understand the mechanism involved in the 4-
HC antimetastatic effect, we carried out a differential dis-
play RT-PCR assay and discovered that 4-HC may be alter-
ing the expression of several genes other than paxillin. In
this work ARM-1 has been identified as one of the genes
differentially expressed in 4-HC-treated cells. ARM-1 is a
ARM-1 expression and adhesion to lung sections by cells treated with 4-HC Figure 6
ARM-1 expression and adhesion to lung sections by cells treated with 4-HC. A. The effect of 4-HC on ARM-1 
expression was evaluated by real time-PCR. 4-HC inhibited ARM-1 mRNA expression. Values are represented as ratios of 
ARM-1/GAPDH ± SD. B. B16-F10 cells were treated as described previously, and then incubated with lung sections during 30 
min to allow their adhesion. The preparations were stained and photographed. Photomicrographs (400X) show that control 
cells (left) were able to adhere to lung sections; in contrast, 4-HC-treated cells (right) displayed impaired adhesion. C. Quanti-
fication of adhered cells (mean ± SE) from 5 independent experiments. On each experiment, 10 fields were counted. ***P < 
0.0001 (Student's t test).Cancer Cell International 2008, 8:8 http://www.cancerci.com/content/8/1/8
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protein associated with the plasma membrane [58,59]
whose precise functions have not been totally solved.
ARM-1 was first discovered as an adhesion promoting
molecule [37,59], but recently it was identified as a novel
component of the 26 S proteasome [60]. The role of ARM-
1 in the regulation of cell adhesion is supported by studies
in which changes in ARM-1 expression alter cell-cell adhe-
sion. For example, overexpression of ARM-1 in endothe-
lial cells increases lymphocyte adhesion [58]. Similarly,
transfection of ARM-1 into kidney embryonic cells pro-
motes their adhesion to endothelial cells [37]. A role of
ARM-1 in metastasis is suggested by the fact that ARM-1
expression is increased in metastatic human breast cancer
cells as compared with their non metastatic counterparts
[37]. Besides, ARM-1 expression is constitutive in cell lines
from gastric carcinoma [59], breast carcinoma, and T lym-
phoma [37]. Together, these data suggest that ARM-1 may
be a metastasis-associated gene. We show that ARM-1
dowregulation produced by 4-HC correlates with a
decreased adhesion of B16-F10 cells to lung sections. This
effect suggests that 4-HC may be inhibiting ARM-1-medi-
ated tumor cell adhesion and/or invasion during the for-
mation of pulmonary metastases. Nevertheless, the role of
ARM-1 reduced expression in the antimetastatic effect of
4-HC needs further investigation. Furthermore, since sev-
eral transcripts were differentially displayed in 4-HC-
treated cells, it cannot be ruled out that 4-HC may be
affecting the expression of other regulatory proteins that
participate in metastasis. In particular, it will be necessary
to clarify the effect of 4-HC on integrin expression since
several of these receptors participate in different stages of
the metastatic cascade.
Conclusion
This study shows that 4-HC inhibits the formation of
experimental metastases. Although the molecular mecha-
nism of the antimetastatic action of 4-HC needs to be fur-
ther defined, our present results indicate that 4-HC-
induced decreased paxillin availability and inappropriate
subcellular localization impair the adequate generation of
signals that promote malignancy. In addition, 4-HC may
affect important steps of metastasis by changing the
expression of other molecules, such as ARM-1. However,
further studies are required to clarify the effects of 4-HC in
vivo since there are not toxicological or pharmacokinetic
data available. Together, our results suggests that 4-HC, or
agents with similar mode of action, might be useful in the
prevention of metastasis and could be used as an adjuvant
in the therapy of melanoma.
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